Genetically engineered dopamine β-hydroxylase gene promoters with better PHOX2-binding sites drive significantly enhanced transgene expression in a noradrenergic cell-specific manner
Authors:
Open Access
- 31 January 2005
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 11 (1) , 132-141
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Genetic Basis of Clinical Catecholamine DisordersAnnals of the New York Academy of Sciences, 2002
- Phox2 genes — from patterning to connectivityCurrent Opinion in Genetics & Development, 2002
- Specification of catecholaminergic and serotonergic neuronsNature Reviews Neuroscience, 2002
- A Proximal Promoter Domain Containing a Homeodomain-Binding Core Motif Interacts with Multiple Transcription Factors, Including HoxA5 and Phox2 Proteins, and Critically Regulates Cell Type-Specific Transcription of the Human Norepinephrine Transporter GeneJournal of Neuroscience, 2002
- A High-Efficiency Synthetic Promoter That Drives Transgene Expression Selectively in Noradrenergic NeuronsHuman Gene Therapy, 2001
- Positive and negative elements contribute to the cell-specific expression of the rat dopamine β-hydroxylase geneMolecular Brain Research, 1996
- Identification of a negative regulatory element in the 5′-flanking region of the human dopamine β-hydroxylase geneMolecular Brain Research, 1995
- Homeodomain-DNA recognitionCell, 1994
- Cell-specific expression from the human dopamine beta-hydroxylase promoter in transgenic mice is controlled via a combination of positive and negative regulatory elementsJournal of Neuroscience, 1994
- Nucleotides flanking a conserved TAAT core dictate the DNA binding specificity of three murine homeodomain proteins.Molecular and Cellular Biology, 1993